{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-013441","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.453142+00:00","generated_at":"2026-06-25T21:55:59.972245+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"COMPASS Pathways reports Q1 2022 net loss of $21.2M; cash $243.7M; FDA end-of-phase II meeting held","bullets":["Net loss $21.2M ($0.50/sh) vs $12.7M ($0.35) in Q1 2021; R&D expenses $15.4M (up from $6.9M).","Cash and cash equivalents $243.7M as of March 31, 2022, down from $273.2M at Dec 31, 2021.","End-of-phase II meeting with FDA completed; finalizing Phase III design for TRD program targeting H2 2022.","Awarded Innovation Passport under UK MHRA ILAP for COMP360 psilocybin therapy.","Phase II trial in PTSD ongoing; collaboration with King's College London and NHS for mental health research."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-013441","json":"https://secwatch.observer/filing/0001628280-22-013441.json","markdown":"https://secwatch.observer/filing/0001628280-22-013441.md","text":"https://secwatch.observer/filing/0001628280-22-013441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828022013441/0001628280-22-013441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828022013441/cmps-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:55:59.972245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}